Compounding Information for States

Why It Matters

Stronger federal‑state coordination improves detection and enforcement against unsafe compounding practices, protecting patients and reducing public‑health risks. The evolving legal framework ensures regulatory actions are transparent and economically balanced for small pharmacies.

Key Takeaways

• FDA shares inspection data and adverse events with state pharmacy boards
• States can email concerns to FDA under DQSA Section 105
• Information‑sharing agreements (Commissioning, 20.88) enable broader data exchange
• Standard MOU addresses interstate distribution of large‑volume compounded drugs
• Court‑ordered rulemaking will assess economic impact on small compounding businesses

Pulse Analysis

The compounding landscape in the United States is a patchwork of federal guidance and state‑level enforcement. While the FDA retains authority over compounded drugs that meet the definition of a drug manufacturer, the day‑to‑day supervision of the thousands of compounding pharmacies falls to state boards of pharmacy. Recognizing this division of labor, the FDA has formalized a series of information‑sharing practices—ranging from real‑time alerts about adverse events to joint inspection teams—that allow states to act swiftly when a compounder poses a patient‑safety threat. This collaborative model leverages the granular, on‑the‑ground insight of state regulators while preserving the FDA’s broader public‑health mandate.

Section 105 of the Drug Quality and Security Act codifies the channel through which states can submit concerns directly to the FDA, typically via the [e-mail] email address. In return, the agency is obligated to notify all relevant state boards when it receives a submission or makes a determination that a pharmacy is violating section 503A. To facilitate deeper data exchange, the FDA encourages states to adopt either a Commissioning agreement or a 20.88 information‑sharing agreement, both of which lift statutory barriers to sharing non‑public information. A standardized memorandum of understanding, introduced in 2020, further clarifies responsibilities for interstate distribution of high‑volume compounded products, though it is currently undergoing notice‑and‑comment rulemaking after a district‑court remand.

The heightened coordination has tangible consequences for compounding businesses. Enhanced visibility into inspection findings and adverse‑event reports means that non‑compliant pharmacies face faster corrective actions, reducing the likelihood of widespread patient harm. At the same time, the pending rulemaking on the MOU promises a more balanced regulatory approach that considers the economic impact on small‑scale compounders, a concern highlighted by recent litigation. For industry stakeholders, staying abreast of state‑level submissions and the evolving information‑sharing agreements is essential to maintaining compliance and safeguarding market reputation in an increasingly scrutinized sector.